Pancreatic Cancer Research

ResearcherTongji HospitalActive in the last 2 years

Bin Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1568-8760; OpenAlex author ID A5083149235. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 0, last author 4)
Trials
4 (principal investigator on 4)
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2019: 1 trial · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper, 1 trial · 2025: 4 papers, 1 trial · 2026: 3 papers, 1 trial

Papers 11

  1. Cancer-Associated Fibroblast-Derived Sphingosine-1-Phosphate Activates a MALL-SDC4 Axis to Facilitate Perineural Invasion in Pancreatic Cancer. Co-author DOI 10.1002/advs.75426↗
  2. Endoscopic ultrasound and clinical features for differentiating autoimmune pancreatitis and pancreatic ductal adenocarcinoma: a multicenter cohort study. Co-author DOI 10.1016/j.gie.2026.07.019↗
  3. CAF-derived PTGDS drives pancreatic cancer neuroendocrine differentiation and chemoresistance via PAQR9-MAPK. Co-author DOI 10.1038/s41389-026-00634-0↗
  4. PPY-Induced iCAFs Cultivate an Immunosuppressive Microenvironment in Pancreatic Cancer. Co-author DOI 10.1002/advs.202413432↗
  5. Revealing the role of cancer-associated fibroblast senescence in prognosis and immune landscape in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.111612↗
  6. Establishing a new-onset diabetes-related metabolism signature for predicting the prognosis and immune landscape in pancreatic cancer. Co-author DOI 10.1093/carcin/bgae072↗
  7. Anti-CTGF/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer. Last author DOI 10.1136/jitc-2025-012144↗
  8. Exosome-derived tRNA fragments tRF-GluCTC-0005 promotes pancreatic cancer liver metastasis by activating hepatic stellate cells. Last author DOI 10.1038/s41419-024-06482-3↗
  9. Diagnostic and Prognostic Values of KRAS Mutations on EUS-FNA Specimens and Circulating Tumor DNA in Patients With Pancreatic Cancer. Last author DOI 10.14309/ctg.0000000000000487↗
  10. Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling. Co-author DOI 10.1186/s12935-021-02390-0↗
  11. Endoscopic ultrasound-guided radiofrequency ablation of unresectable pancreatic cancer with low ablation power and multiple applications: a preliminary study o… Last author DOI 10.21037/apm-20-1468↗

Trials 4

  1. EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases Principal investigator NCT07448376↗
  2. 22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions Principal investigator NCT07012694↗
  3. 22G-Adapt Needle Biopsy Versus Fine-needle Aspiration in Endoscopic Ultrasound-guided Sampling of Solid Lesions Principal investigator NCT06563232↗
  4. Comparing of a 22G EUS Procore Fine Needle Biopsy Device and a 20G EUS Procore Fine Needle Biopsy Device Principal investigator NCT03803930↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuchong Zhao · 10 shared papers, 2021–2026 · strength 1.99
  2. Mengdie Cao · 7 shared papers, 2024–2026 · strength 1.57
  3. Jingwen Liang · 7 shared papers, 2024–2026 · strength 1.57
  4. Luyao Liu · 6 shared papers, 2024–2026 · strength 1.35
  5. Shiru Chen · 5 shared papers, 2025–2026 · strength 1.15
  6. Wang Peng · 4 shared papers, 2025–2026 · strength 0.93
  7. Zhou Luan · 4 shared papers, 2021–2026 · strength 0.79
  8. Ronghua Wang · 3 shared papers, 2022–2025 · strength 0.59
  9. Jinlin Wang · 3 shared papers, 2021–2025 · strength 0.51
  10. Lu Zhou · 1 shared paper, 2026 · strength 0.27
  11. Dongqiang Zhao · 1 shared paper, 2026 · strength 0.27
  12. Yuheng Zhang · 1 shared paper, 2026 · strength 0.27
  13. Aiming Yang · 1 shared paper, 2026 · strength 0.27
  14. Yilei Yang · 1 shared paper, 2025 · strength 0.22
  15. Wei Chen · 1 shared paper, 2025 · strength 0.22
  16. Wei Chen · 1 shared paper, 2024 · strength 0.19
  17. Yun Wang · 1 shared paper, 2021 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.